ClinicalTrials.gg
CompletedNCT02176356Updated Jan 9, 2019Results posted

Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)

A Phase 4 interventional study of onabotulinumtoxinA and bimatoprost ophthalmic solution 0.03% in Facial Rhytides, Crow's Feet Lines and Glabellar Lines, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 35 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-01-09.

Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
116
Allocation
Not applicable
Ages
35 Years to 65 Years
Sex
All
01

Study summary

A study to evaluate patient satisfaction, aesthetic and psychological impact of combined treatment with BOTOX® Cosmetic (onabotulinumtoxinA), JUVÉDERM® ULTRA XC, JUVÉDERM® ULTRA PLUS XC, JUVÉDERM® VOLUMA® XC, and LATISSE® (bimatoprost ophthalmic solution).

02

Conditions studied

  • Facial Rhytides
  • Crow's Feet Lines
  • Glabellar Lines
  • Nasolabial Fold
03

In context

Lead sponsor

Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.

First submitted before Allergan became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Qualified to receive treatment with BOTOX® Cosmetic, a facial filler (JUVÉDERM® ULTRA XC and/or JUVÉDERM® ULTRA Plus XC and/or JUVÉDERM® VOLUMA® XC) and LATISSE® treatment
  • Naïve to botulinum toxin therapy of any serotype for any indication
  • Naïve to prescription eyelash growth products of any type
  • Naïve to dermal filler treatment in the face and neck

Exclusion criteria

Exclusion Criteria:

  • Undergone facial plastic surgery, tissue grafting, tissue augmentation or facial dermal filler injections
  • Had laser, photomodulation, intense pulsed light, radio frequency, dermabrasion or chemical peel in the face or neck
  • Have received skin resurfacing (laser, photomodulation, intense pulsed light, radio frequency, dermabrasion, chemical peel, or non-ablative procedures) in the face or neck within 3 months
  • Systemic retinoid therapy within 1 year prior to study enrollment
  • Presence of inflammation at the proposed injection site(s)
  • Profound atrophy/excessive weakness of muscles in target areas of injection
  • Known immunization or to any botulinum toxin serotype
  • Undergone oral surgery or dental procedures within 30 days
  • No visible eyelashes
  • Use of permanent eyeliner, eyelash implants, semi-permanent eyelash tint, dye or extension
  • Use of prescription eyelash growth products
  • Unwilling or unable to remove contact lenses prior to study medication application in the evening and keep lenses out for 30 minutes
  • Diagnosis of myasthenia gravis, Eaton-Lambert Syndrome, amyotrophic lateral sclerosis, or any other disease that might interfere with neuromuscular function.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
Single (Outcomes assessor)
Enrollment
116 participants (actual)

Study arms

  • Other
    All Participants

    JUVÉDERM® ULTRA XC and/or JUVÉDERM® ULTRA PLUS XC and/or JUVÉDERM® VOLUMA® XC injection into facial areas, volume as determined by the investigator on Day 1 with additional treatment at Day 14 if applicable. LATISSE® 1 drop applied to upper eyelid at the base of the eyelashes once daily in the evening for 17 weeks beginning on Day 1. BOTOX® Cosmetic 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas at Month 3.

    Biological: onabotulinumtoxinA · Drug: bimatoprost ophthalmic solution 0.03% · Device: JUVÉDERM® ULTRA XC · Device: JUVÉDERM® ULTRA PLUS XC · Device: JUVÉDERM® VOLUMA® XC

Interventions

  • onabotulinumtoxinA (BOTOX® Cosmetic) 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas.

    Also known as: botulinum toxin Type A

  • bimatoprost ophthalmic solution 0.03% (LATISSE®) 1 drop applied to the upper eyelid at the base of eyelashes once daily in the evening for 17 weeks.

    Also known as: LATISSE®

  • DeviceJUVÉDERM® ULTRA XC

    JUVÉDERM® ULTRA XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.

  • DeviceJUVÉDERM® ULTRA PLUS XC

    JUVÉDERM® ULTRA PLUS XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.

  • DeviceJUVÉDERM® VOLUMA® XC

    JUVÉDERM® VOLUMA® XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Satisfaction With Facial Appearance Overall Using a 10-item Questionnaire

    Participants assessed their satisfaction with the way they look right now with their entire face in mind using a 10-item questionnaire. Possible responses to each question were: 1=Very dissatisfied, 2=Somewhat dissatisfied, 3-=Somewhat satisfied and 4=Very satisfied. The responses were added across items and transformed to a Rasch scale ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement.

    Time frame: Baseline, Month 4

Secondary outcomes

  1. Change From Baseline in Aging Appearance Using a 7-item Questionnaire

    Participants rated how they look now using a 7-item questionnaire. Possible responses for each question are 1=Definitely disagree, 2=Somewhat disagree, 3=Somewhat agree or 4=Definitely agree. The responses were added across items and transformed to a Rasch score ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement.

    Time frame: Baseline, Month 4

  2. Change From Baseline in Age Appraisal Using a Visual Analogue Scale (VAS)

    Participants assessed how old they think they look compared to their actual age using a VAS by placing a mark on a number on a horizontal line where the far left of the line= -15 (look 15 years younger), 0=look current age, to the far right of the line=15 (look 15 years older). A positive change from Baseline indicates improvement.

    Time frame: Baseline, Month 4

  3. Change From Baseline in Social Confidence Using an 8-item Questionnaire

    Participants assessed their social confidence with their facial appearance in mind in the past week using an 8-item questionnaire. Possible responses for each question are 1=Definitely disagree, 2=Somewhat disagree, 3=Somewhat agree or 4= Definitely agree. The responses were added across items and transformed to a Rasch score ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement.

    Time frame: Baseline, Month 4

  4. Change From Baseline in Psychological Well-Being Using a 10-item Questionnaire

    Participants assessed their psychological well-being with their facial appearance in mind using a 10-item questionnaire. Possible responses for each question are 1=Definitely disagree, 2=Somewhat disagree, 3=Somewhat agree or 4= Definitely agree. The responses were added across items and transformed to a Rasch score ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement.

    Time frame: Baseline, Month 4

  5. Participant's Self- Perception of Age (SPA)

    Participants assessed SPA by answering the question: How do you think your facial appearance looks compared to your age today? Participants recorded how many years younger or older they thought their facial appearance made them look. A negative result indicates improvement (a younger appearance).

    Time frame: Baseline, Month 4

  6. Change From Baseline in Investigator's Assessment of Severity of Glabellar Lines (GLs) at Maximum Frown Using the Facial Wrinkle Scale (FWS)

    The investigator assessed the severity of the participant's GLs using the 4-point FWS where: 0=None, 1=Mild, 2=Moderate or 3=Severe. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Month 4

  7. Change From Baseline in Investigator's Assessment of the Severity of Crow's Feet Lines (CFLs) at Maximum Smile Using the FWS

    The investigator assessed the severity of the participant's CFLs using the 4-point FWS where: 0=None, 1=Mild, 2=Moderate or 3=Severe. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Month 4

  8. Change From Baseline in Investigator's Global Eyelash Assessment Score (GEAS)

    The investigator assessed the participant's eyelash prominence using the 4-point GEAS where: 1=Minimal (worst), 2=Moderate, 3=Marked and 4=Very Marked (best). A positive change from Baseline indicates improvement.

    Time frame: Baseline, Month 4

  9. Change From Baseline in the Investigator's Assessment of the Participant's Overall Mid-Face Volume Deficit Using the 6-Point MFVDS

    The investigator assessed overall mid-face volume deficit using the Mid-face Volume Deficit Scale (MFVDS) where: 0=None (moon face; fullness) \[best\], 1=Minimal (flattening), 2=Mild (mild concavity), 3=Moderate (moderate concavity, 4=Significant (significant concavity) and 5=Severe (wasting) \[worst\]. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Month 4

  10. Change From Baseline in the Investigator's Assessment of the Participant's Nasolabial Folds Severity

    The investigator assessed the participants nasolabial folds severity using the 5-Point Nasolabial Fold Severity (NLFS) Scale where: 0=None (no wrinkles) \[best\], 1=Mild (shallow, just perceptible wrinkle), 2=Moderate (moderately deep wrinkle), 3=Severe (deep wrinkle) or 4= Extreme (very deep wrinkle). A negative change from Baseline indicates improvement.

    Time frame: Baseline, Month 4

  11. Change From Baseline in the Investigator's Assessment of the Participant's Oral Commissures Severity

    The investigator assessed the participant's oral commissure using the 4-Point Oral Commissure Severity Scale (OCSS) where: 0=None, 1=Mild, 2=Moderate or 3=Severe. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Month 4

  12. Change From Baseline in the Investigator's Assessment of the Participant's Perioral Lines Severity

    The investigator assessed the participant's perioral lines severity using the 4-Point Perioral Lines at Rest Severity Scale (POLSS) where: 0=None (no lines) \[best\], 1=Mild (few, shallow lines), 2=Moderate (some moderate lines) or 3=Severe (many deep lines or crevices)\[worst\]. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Month 4

  13. Change From Baseline in the Participant Satisfaction With Appearance of Periorbital Area

    Participants assessed how their overall eye appearance has affected them over the past 7 days using the 9-item Periorbital Aesthetic Appearance Questionnaire (PAAQ). Possible responses to each question were: 0=Never (best), 1=Rarely, 2=Some of the time, 3=Most of the time and 4=All of the time with a total possible score of 0 to 36. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Month 4

07

Results

Posted Jun 16, 2016

Participant flow

Participant flow — Overall Study
MilestoneAll Participants
Started116
Eligible and received treatment100
Completed93
Not completed23
Withdrew: Screen failure14
Withdrew: Lost to follow-up4
Withdrew: Personal reasons3
Withdrew: Other miscellaneous reasons2

Outcome measures

PrimaryChange From Baseline in Satisfaction With Facial Appearance Overall Using a 10-item Questionnaire

Participants assessed their satisfaction with the way they look right now with their entire face in mind using a 10-item questionnaire. Possible responses to each question were: 1=Very dissatisfied, 2=Somewhat dissatisfied, 3-=Somewhat satisfied and 4=Very satisfied. The responses were added across items and transformed to a Rasch scale ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement.

Time frame:
Baseline, Month 4
Reported as:
Mean · score on a scale
Change From Baseline in Satisfaction With Facial Appearance Overall Using a 10-item Questionnaire
score on a scaleAll Participants
Baseline41.22 ± 11.97
Change from Baseline at Month 431.70 ± 20.00
SecondaryChange From Baseline in Aging Appearance Using a 7-item Questionnaire

Participants rated how they look now using a 7-item questionnaire. Possible responses for each question are 1=Definitely disagree, 2=Somewhat disagree, 3=Somewhat agree or 4=Definitely agree. The responses were added across items and transformed to a Rasch score ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement.

Time frame:
Baseline, Month 4
Reported as:
Mean · score on a scale
Change From Baseline in Aging Appearance Using a 7-item Questionnaire
score on a scaleAll Participants
Baseline45.07 ± 18.85
Change from Baseline at Month 428.47 ± 21.47
SecondaryChange From Baseline in Age Appraisal Using a Visual Analogue Scale (VAS)

Participants assessed how old they think they look compared to their actual age using a VAS by placing a mark on a number on a horizontal line where the far left of the line= -15 (look 15 years younger), 0=look current age, to the far right of the line=15 (look 15 years older). A positive change from Baseline indicates improvement.

Time frame:
Baseline, Month 4
Reported as:
Mean · years
Change From Baseline in Age Appraisal Using a Visual Analogue Scale (VAS)
yearsAll Participants
Baseline0.1 ± 4.28
Change from Baseline at Month 4 (n=92)-4.6 ± 4.36
SecondaryChange From Baseline in Social Confidence Using an 8-item Questionnaire

Participants assessed their social confidence with their facial appearance in mind in the past week using an 8-item questionnaire. Possible responses for each question are 1=Definitely disagree, 2=Somewhat disagree, 3=Somewhat agree or 4= Definitely agree. The responses were added across items and transformed to a Rasch score ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement.

Time frame:
Baseline, Month 4
Reported as:
Mean · score on a scale
Change From Baseline in Social Confidence Using an 8-item Questionnaire
score on a scaleAll Participants
Baseline62.70 ± 21.74
Change from Baseline at Month 418.24 ± 23.04
SecondaryChange From Baseline in Psychological Well-Being Using a 10-item Questionnaire

Participants assessed their psychological well-being with their facial appearance in mind using a 10-item questionnaire. Possible responses for each question are 1=Definitely disagree, 2=Somewhat disagree, 3=Somewhat agree or 4= Definitely agree. The responses were added across items and transformed to a Rasch score ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement.

Time frame:
Baseline, Month 4
Reported as:
Mean · score on a scale
Change From Baseline in Psychological Well-Being Using a 10-item Questionnaire
score on a scaleAll Participants
Baseline62.78 ± 22.45
Change from Baseline at Month 419.89 ± 20.63
SecondaryParticipant's Self- Perception of Age (SPA)

Participants assessed SPA by answering the question: How do you think your facial appearance looks compared to your age today? Participants recorded how many years younger or older they thought their facial appearance made them look. A negative result indicates improvement (a younger appearance).

Time frame:
Baseline, Month 4
Reported as:
Mean · years
Participant's Self- Perception of Age (SPA)
yearsAll Participants
Baseline0.2 ± 4.08
Month 4-4.6 ± 4.19
SecondaryChange From Baseline in Investigator's Assessment of Severity of Glabellar Lines (GLs) at Maximum Frown Using the Facial Wrinkle Scale (FWS)

The investigator assessed the severity of the participant's GLs using the 4-point FWS where: 0=None, 1=Mild, 2=Moderate or 3=Severe. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Month 4
Reported as:
Mean · score on a scale
Change From Baseline in Investigator's Assessment of Severity of Glabellar Lines (GLs) at Maximum Frown Using the Facial Wrinkle Scale (FWS)
score on a scaleAll Participants
Baseline2.6 ± 0.50
Change from Baseline at Month 4-1.6 ± 0.78
SecondaryChange From Baseline in Investigator's Assessment of the Severity of Crow's Feet Lines (CFLs) at Maximum Smile Using the FWS

The investigator assessed the severity of the participant's CFLs using the 4-point FWS where: 0=None, 1=Mild, 2=Moderate or 3=Severe. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Month 4
Reported as:
Mean · score on a scale
Change From Baseline in Investigator's Assessment of the Severity of Crow's Feet Lines (CFLs) at Maximum Smile Using the FWS
score on a scaleAll Participants
Left_Baseline2.5 ± 0.50
Left_Change from Baseline at Month 4-1.0 ± 0.85
Right_Baseline2.5 ± 0.50
Right_Change from Baseline at Month 4-1.0 ± 0.85
SecondaryChange From Baseline in Investigator's Global Eyelash Assessment Score (GEAS)

The investigator assessed the participant's eyelash prominence using the 4-point GEAS where: 1=Minimal (worst), 2=Moderate, 3=Marked and 4=Very Marked (best). A positive change from Baseline indicates improvement.

Time frame:
Baseline, Month 4
Reported as:
Mean · score on a scale
Change From Baseline in Investigator's Global Eyelash Assessment Score (GEAS)
score on a scaleAll Participants
Baseline1.8 ± 0.42
Change from Baseline at Month 41.5 ± 0.65
SecondaryChange From Baseline in the Investigator's Assessment of the Participant's Overall Mid-Face Volume Deficit Using the 6-Point MFVDS

The investigator assessed overall mid-face volume deficit using the Mid-face Volume Deficit Scale (MFVDS) where: 0=None (moon face; fullness) \[best\], 1=Minimal (flattening), 2=Mild (mild concavity), 3=Moderate (moderate concavity, 4=Significant (significant concavity) and 5=Severe (wasting) \[worst\]. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Month 4
Reported as:
Mean · score on a scale
Change From Baseline in the Investigator's Assessment of the Participant's Overall Mid-Face Volume Deficit Using the 6-Point MFVDS
score on a scaleAll Participants
Baseline3.1 ± 0.36
Change from Baseline at Month 4-1.7 ± 0.80
SecondaryChange From Baseline in the Investigator's Assessment of the Participant's Nasolabial Folds Severity

The investigator assessed the participants nasolabial folds severity using the 5-Point Nasolabial Fold Severity (NLFS) Scale where: 0=None (no wrinkles) \[best\], 1=Mild (shallow, just perceptible wrinkle), 2=Moderate (moderately deep wrinkle), 3=Severe (deep wrinkle) or 4= Extreme (very deep wrinkle). A negative change from Baseline indicates improvement.

Time frame:
Baseline, Month 4
Reported as:
Mean · score on a scale
Change From Baseline in the Investigator's Assessment of the Participant's Nasolabial Folds Severity
score on a scaleAll Participants
Baseline2.6 ± 0.51
Change from Baseline at Month 4-1.0 ± 0.85
SecondaryChange From Baseline in the Investigator's Assessment of the Participant's Oral Commissures Severity

The investigator assessed the participant's oral commissure using the 4-Point Oral Commissure Severity Scale (OCSS) where: 0=None, 1=Mild, 2=Moderate or 3=Severe. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Month 4
Reported as:
Mean · score on a scale
Change From Baseline in the Investigator's Assessment of the Participant's Oral Commissures Severity
score on a scaleAll Participants
Baseline2.1 ± 0.49
Change from Baseline at Month 4-0.9 ± 0.67
SecondaryChange From Baseline in the Investigator's Assessment of the Participant's Perioral Lines Severity

The investigator assessed the participant's perioral lines severity using the 4-Point Perioral Lines at Rest Severity Scale (POLSS) where: 0=None (no lines) \[best\], 1=Mild (few, shallow lines), 2=Moderate (some moderate lines) or 3=Severe (many deep lines or crevices)\[worst\]. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Month 4
Reported as:
Mean · score on a scale
Change From Baseline in the Investigator's Assessment of the Participant's Perioral Lines Severity
score on a scaleAll Participants
Baseline2.0 ± 0.57
Change from Baseline at Month 4-1.1 ± 0.68
SecondaryChange From Baseline in the Participant Satisfaction With Appearance of Periorbital Area

Participants assessed how their overall eye appearance has affected them over the past 7 days using the 9-item Periorbital Aesthetic Appearance Questionnaire (PAAQ). Possible responses to each question were: 0=Never (best), 1=Rarely, 2=Some of the time, 3=Most of the time and 4=All of the time with a total possible score of 0 to 36. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Month 4
Reported as:
Mean · score on a scale
Change From Baseline in the Participant Satisfaction With Appearance of Periorbital Area
score on a scaleAll Participants
Baseline21.1 ± 6.71
Change from Baseline at Month 4-12.6 ± 7.61

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Participants—0/100 (0%)18/100 (18%)
Most frequent other events
Most frequent other events
EventAll Participants
ContusionInjury, poisoning and procedural complications18/100

Baseline characteristics

Safety population included all enrolled participants who received any study treatment.

Age, Continuous
Age, Continuous(years)All Participants
Mean52.5 ± 7.40
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female96
Male4
08

Study locations

1 site
  • Los Angeles, California, United States
09

References and documents

Publications

  • Weinkle SH, Werschler WP, Teller CF, Sykes JM, Shamban A, Rivkin A, Narurkar VA, Kaminer MS, Dayan S, Cohen JL, Gallagher CJ. Impact of Comprehensive, Minimally Invasive, Multimodal Aesthetic Treatment on Satisfaction With Facial Appearance: The HARMONY Study. Aesthet Surg J. 2018 Apr 6;38(5):540-556. doi: 10.1093/asj/sjx179. PubMed 29244069 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2014 to primary completion in May 2015, 10 months.

Results were first posted in Jun 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2014
First posted
Jun 27, 2014
StartActual
Jun 30, 2014
Primary completionActual
May 3, 2015
CompletionActual
May 3, 2015
Results first posted
Jun 16, 2016
Last update
Jan 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02176356
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Jun 27, 2014
Start date
Jun 30, 2014
Primary completion
May 3, 2015
Completion
May 3, 2015
Results posted
Jun 16, 2016
Last update
Jan 9, 2019

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimatoprost Ophthalmic Solution

Start the discussion